In a move that underscores the growing sophistication of regional life-science ventures, Phoenixville-based PleoPharma, Inc. has announced the closing of a $36 million Series B financing round, putting fresh fuel behind its lead asset, PP-01, as the company advances toward Phase 3 trials in a high-unmet-need indication: cannabis use disorder (CUD) and the associated withdrawal syndrome (CWS).
The round — led by biotech specialist funds alongside a generalist investor and strong participation from Series A backers — signals investor confidence in both the company’s asset and the broader addiction-therapeutics space. According to PleoPharma’s press release, the proceeds will specifically support the Phase 3 program for patients diagnosed with CUD.
Co-founder and CEO Ginger Constantine MD framed the opportunity bluntly: “Recent government data from SAMHSA reported that cannabis addiction continues to accelerate with over 20 million people reported to have Cannabis Use Disorder in the US, an underserved population with no effective or FDA approved solution. We are grateful to have the partnership of this incredible group of new and existing investors who share our commitment to deliver first in class treatments for those with cannabis addiction and withdrawal.”
This follows a string of positive developmental milestones — including U.S. Patent issuances and Fast Track designation from the U.S. Food & Drug Administration (FDA) — positioning PleoPharma as a compelling player in an emerging niche of the addiction-treatment market.
PleoPharma is targeting an important void in treatment: while cannabis use and dependence have grown, there are currently no FDA-approved medications for cannabis withdrawal or CUD. As the company notes, more than 20 million Americans are estimated to have CUD, a number that is rising year on year.
Their investigational agent, PP-01, is a once-daily oral product with a dual mechanism of action — designed to engage suppressed CB1 receptors and address neurotransmitter dysregulation in the mesolimbic reward pathway. The aim: reduce withdrawal symptoms and support abstinence in patients seeking to discontinue cannabis use.
Earlier studies provide encouraging data: In the Phase 2b CAN-002 trial, PleoPharma reported statistically significant reductions in cannabis-withdrawal scores (P < 0.02) and a five-fold greater abstinence rate two weeks post-treatment compared with placebo. The asset was well-tolerated, with no serious adverse events reported.
In February 2025 the FDA granted Fast Track designation to PP-01, helping expedite development and review — a clear signal of the unmet need and the potential clinical value. PleoPharma also strengthened its IP position with U.S. patents related to treatment methods for CWS.
For Greater Philadelphia’s biotech ecosystem, this financing round is another example of a local company successfully attracting significant venture capital and advancing from preclinical/early-clinical to late-stage development. PleoPharma’s footprint in Phoenixville brings visibility to the region’s base of neuropsych-addiction research, therapeutic innovation and capital formation.
For executives and hiring leads in the biopharma cluster, the implications are twofold: Talent opportunity: As PleoPharma advances into Phase 3, it will likely ramp up hiring across clinical operations, regulatory affairs, data science and commercialization planning — presenting openings for local and regional talent pools. Ecosystem signal: The “first-in-class” ambition and milestone financing reflect investor appetite for niche addiction and neuroscience therapeutic areas beyond the headline oncology/rare-disease sectors.
Observers will be watching several key developments: the timeline and design of PleoPharma’s pivotal Phase 3 trial; the company’s regulatory and commercial positioning as the first to potentially bring an FDA-approved therapy for cannabis withdrawal; and any future partnerships that could accelerate market access. As PleoPharma continues to grow, its success story reinforces the strength and innovation emerging from the Philadelphia-area biotech community.
